Type of security: Stock
Sector: Health Care
Industry: Medical Specialities
The data is delayed by 15 minutes.
ENZ is in the long-term down -72% below S&P in 3 years.
Description: Enzo Biochem, Inc., an integrated life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. This segment operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 35 patient service centers in New York and New Jersey; and a standalone laboratory in the New York, as well as a full-service phlebotomy, in-house logistics department, and information technology department. The Life Sciences segment manufactures, develops, and markets products and tools to life sciences, drug developmen
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-3.7%||Sales Growth - Q/Q||3.87%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-23.75%||ROE||-40.8%||ROI|
|Current Ratio||1.6||Quick Ratio||1.25||Long Term Debt/Equity||Debt Ratio||0.66|
|Gross Margin||43.84%||Operating Margin||-13.29%||Net Profit Margin||-14.35%||Dividend Payout Ratio|
|Cash From Financing Activities||6.37 M||Cash From Investing Activities||-1.17 M||Cash From Operating Activities||-8.17 M||Gross Profit||10.48 M|
|Net Profit||-2.91 M||Operating Profit||-2.85 M||Total Assets||58.52 M||Total Current Assets||36.06 M|
|Total Current Liabilities||22.54 M||Total Debt||3.41 M||Total Liabilities||24.46 M||Total Revenue||23.99 M|
|High 52 week||4.94||Low 52 week||2.46||Last close||3.73||Last change||1.08%|
|RSI||51.34||Average true range||0.25||Beta||1.59||Volume||42.07 K|
|Simple moving average 20 days||-0.2%||Simple moving average 50 days||0.3%||Simple moving average 200 days||10.75%|
|Performance Week||6.27%||Performance Month||2.75%||Performance Quart||0.54%||Performance Half||-6.98%|
|Performance Year||-7.44%||Performance Year-to-date||34.17%||Volatility daily||4.26%||Volatility weekly||9.51%|
|Volatility monthly||19.5%||Volatility yearly||67.55%||Relative Volume||117.6%||Average Volume||243.91 K|
|New High||New Low|
2019-11-09 09:18:41 | What Kind Of Shareholders Own Enzo Biochem, Inc. NYSE:ENZ?
2019-10-17 20:44:48 | Edited Transcript of ENZ earnings conference call or presentation 15-Oct-19 8:30pm GMT
2019-10-15 16:15:00 | Enzo Biochem Reports Fiscal Fourth Quarter and Full Year Financial Results
2019-10-10 08:06:32 | Does Enzo Biochem, Inc.'s NYSE:ENZ CEO Salary Reflect Performance?
2019-09-24 09:00:00 | New York State Health Department Approves Hepatitis B Virus Quantitative Clinical Assay
2019-09-10 07:33:05 | Investors Who Bought Enzo Biochem NYSE:ENZ Shares Five Years Ago Are Now Down 41%
2019-08-15 07:43:03 | Is Enzo Biochem NYSE:ENZ Using Debt In A Risky Way?
2019-07-17 10:48:57 | Is Enzo Biochem, Inc.'s NYSE:ENZ 2.3% ROE Worse Than Average?
2019-06-19 00:41:53 | Edited Transcript of ENZ earnings conference call or presentation 11-Jun-19 12:30pm GMT
2019-06-11 14:54:18 | What Kind Of Share Price Volatility Should You Expect For Enzo Biochem, Inc. NYSE:ENZ?
2019-06-11 06:30:00 | Enzo Biochem, Inc. to Host Earnings Call
2019-06-10 16:17:00 | Enzo Biochem Reports Fiscal Third Quarter and Nine Months Operating Results
2019-05-02 06:00:00 | Biotech Bets and a Goodbye from a Favorite Expert
2019-04-23 14:19:42 | What Percentage Of Enzo Biochem, Inc. NYSE:ENZ Shares Do Insiders Own?
2019-03-12 19:35:20 | Edited Transcript of ENZ earnings conference call or presentation 12-Mar-19 12:30pm GMT
2019-03-11 16:50:44 | Enzo Biochem: Fiscal 2Q Earnings Snapshot
2019-02-26 12:45:59 | Why Enzo Biochem, Inc.’s NYSE:ENZ CEO Pay Matters To You
2019-01-29 07:35:00 | Factors of Influence in 2019, Key Indicators and Opportunity within The Hain Celestial Group, Allegheny Technologies, NVR, Greif, CorMedix, and Enzo Biochem — New Research Emphasizes Economic Growth
2019-01-02 13:40:08 | How Many Insiders Bought Enzo Biochem, Inc. NYSE:ENZ Shares?
2018-12-17 18:57:48 | Edited Transcript of ENZ earnings conference call or presentation 11-Dec-18 1:30pm GMT
2018-12-10 16:21:31 | Enzo Biochem: Fiscal 1Q Earnings Snapshot
2018-12-10 16:15:00 | Enzo Biochem Reports Fiscal 2019 First Quarter Results
2018-11-14 12:57:36 | What Kind Of Shareholder Owns Most Enzo Biochem Inc NYSE:ENZ Stock?
2018-10-29 08:25:00 | Market Trends Toward New Normal in Polaris Industries, NIKE, Charles River Laboratories International, Actuant, Caesarstone, and Enzo Biochem — Emerging Consolidated Expectations, Analyst Ratings
2018-10-17 08:15:53 | The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise
2018-10-16 21:42:52 | Edited Transcript of ENZ earnings conference call or presentation 16-Oct-18 12:30pm GMT
2018-10-16 06:30:00 | Enzo Biochem, Inc. to Host Earnings Call
2018-10-15 16:20:31 | Enzo Biochem: Fiscal 4Q Earnings Snapshot
2018-10-15 16:05:00 | Enzo Biochem Reports Fourth Quarter and Fiscal 2018 Results
2018-10-03 19:33:00 | Top 5 Biotech Stocks for 2018
2018-09-05 18:50:00 | Top 5 Biotech Stocks for 2018
2018-08-02 08:15:00 | Market Trends Toward New Normal in Sandy Spring, Tupperware Brands, Dolby Laboratories, AeroVironment, Barnes Group, and Enzo Biochem — Emerging Consolidated Expectations, Analyst Ratings
2018-07-11 19:05:00 | Top 5 Biotech Stocks for 2018
2018-06-12 18:13:22 | Edited Transcript of ENZ earnings conference call or presentation 12-Jun-18 12:30pm GMT